▼ Bezlotoxumab for prevention of recurrence of Clostridium difficile infection.

@article{2018BF,
  title={▼ Bezlotoxumab for prevention of recurrence of Clostridium difficile infection.},
  author={},
  journal={Drug and therapeutics bulletin},
  year={2018},
  volume={56 5},
  pages={
          57-60
        }
}
Clostridium difficile infection is a significant cause of infectious diarrhoea and is associated with considerable morbidity and mortality.1,2 Management of Clostridium difficile infection often requires treatment with antibiotics (metronidazole, vancomycin or fidaxomicin) alongside supportive care to manage hydration, electrolytes and nutrition. However, the risk of recurrence is approximately 20%.2 Here, we review the evidence for bezlotoxumab (▼ Zinplava - Merck Sharp & Dohme Limited), a… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…